Buiten het ziekenhuis opgelopen pneumonie; geen reden om huidige antibioticumrichtlijn te herzien

Translated title of the contribution: Community-acquired pneumonia; no reason to revise current dutch antibiotic guidelines

J. J. Oosterheert*, M. J.M. Bonten, M. M.E. Schneider, I. M. Hoepelman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

Community-acquired pneumonia is an important cause of hospital admission and mortality in the adult population. -The recommended antibiotic for pneumonia caused by Streptococcus pneumoniae is a β-lactam antibiotic and, for so-called atypical pathogens, a macrolide. In the US and elsewhere, the current recommendation is to start with a β-lactam antibiotic and a macrolide or with one of the new quinolones. The available literature consists largely of retrospective studies. Because of possible selection bias in these analyses and inconsistencies in reported outcomes, it is not possible to draw any well-founded conclusions from these studies. Reasons for a possible additional benefit of adding a macrolide to the therapy could include: a higher prevalence of undiagnosed atypical pathogens, the anti-inflammatory effects of macrolides, and resistance of the main pathogens against β-lactam antibiotics. None of these appear to play a significant role. There is no need to revise Dutch guidelines.

Translated title of the contributionCommunity-acquired pneumonia; no reason to revise current dutch antibiotic guidelines
Original languageDutch
Pages (from-to)381-386
Number of pages6
JournalNederlands Tijdschrift voor Geneeskunde
Volume147
Issue number9
Publication statusPublished - 1 Mar 2003

Fingerprint

Dive into the research topics of 'Community-acquired pneumonia; no reason to revise current dutch antibiotic guidelines'. Together they form a unique fingerprint.

Cite this